Welcome to our dedicated page for Sanara Medtech SEC filings (Ticker: SMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sanara MedTech Inc. filings document a Nasdaq-listed medical technology company focused on surgical products for wound care, wound irrigation and bone fusion. Current Reports on Form 8-K record quarterly and annual results, preliminary financial information, investor presentations, strategic priorities, material-event disclosures and exhibits tied to press releases.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation and shareholder voting. The filing record also includes disclosure categories for material agreements, capital structure, operating results and business realignment, including discontinued operations treatment for Tissue Health Plus.
Waldrop Jacob A. reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Chief Operating Officer Jacob A. Waldrop received a grant of 13,956 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. Following this equity award, his direct holdings total 24,755 shares of common stock.
The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22 of 2027, 2028 and 2029, provided he remains employed by Sanara MedTech through each vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Taylor Elizabeth B reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. granted its Chief Financial Officer, Elizabeth B. Taylor, 12,687 shares of restricted common stock as equity compensation. These shares were awarded at no cash cost and increase her direct holdings to 17,632 common shares following the transaction.
The restricted stock will vest in three equal installments, with one-third vesting on March 22 of 2027, 2028, and 2029, respectively. Vesting is conditioned on her continued employment with Sanara MedTech through each vesting date, aligning a portion of her compensation with the company’s long-term performance.
Yon Seth D reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Chief Executive Officer Yon Seth D received a grant of 25,430 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. Following this award, he directly holds 113,398 common shares.
The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, provided he remains employed by the company through each vesting date. This represents compensation rather than an open-market share purchase.
Sanara MedTech Inc. reported a routine equity compensation event for its Chief Executive Officer, Yon Seth D. On the vesting of 2,082 shares of previously granted restricted stock, the company withheld 596 shares of common stock to cover tax obligations, using a per-share value of $18.87. The footnote clarifies that no shares were issued or sold on the market in this transaction. Following the tax-withholding disposition, the CEO directly owns 87,968 shares of Sanara MedTech common stock.
Sanara MedTech Inc. Chief Executive Officer Seth D. Yon filed an amended insider report updating a prior tax-related share withholding. The company withheld 414 shares of common stock at $20.44 per share to cover taxes on the vesting of 1,446 restricted shares, correcting an earlier filing that had shown 491 shares withheld. This was a tax-withholding disposition only, and the filing states that no shares were issued or sold in the transaction. After this adjustment, Yon directly holds 88,564 shares of Sanara MedTech common stock.
Sanara MedTech Inc.’s Chief Executive Officer, Yon Seth D, reported a Form 4 showing a tax-withholding disposition of 491 shares of common stock on March 1, 2026. These shares were withheld by the company to cover tax obligations from the annual vesting of 1,446 previously granted restricted shares, at a reference price of $20.44 per share. The filing notes that no shares were issued or sold in this transaction, and the CEO’s directly held stake after the withholding was 88,487 common shares.
Sanara MedTech Inc. filed a current report to furnish an investor presentation it plans to use with investors and analysts, including at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026. The presentation, attached as Exhibit 99.1, outlines the company’s priorities, strategy and anticipated revenue for fiscal 2026.
The company notes this information is being furnished under Regulation FD, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other Securities Act or Exchange Act filings.
Sanara MedTech Inc. director and Chief Executive Officer Yon Seth D reported a tax-related share withholding tied to restricted stock vesting. The company withheld 873 shares of common stock to cover tax obligations when 3,049 previously granted restricted shares vested, and no shares were issued or sold in the market. After this withholding, Yon Seth D directly owns 88,978 shares of Sanara MedTech common stock.
Sanara MedTech Inc.’s Chief Operating Officer Jacob A. Waldrop reported an automatic share withholding related to equity compensation. On the transaction date, 714 shares of common stock were withheld by the company at $19.90 per share to cover tax obligations from the annual vesting of 2,930 restricted stock shares previously granted to him. The filing states that no shares were issued or sold in the open market as part of this tax-withholding disposition, and Waldrop’s direct holdings after the transaction total 10,799 common shares.
Sanara MedTech Inc. Chief Financial Officer Elizabeth B. Taylor reported a tax-related share disposition tied to vesting of restricted stock. On the vesting of 1,794 restricted shares, the company withheld 437 shares of common stock at $19.90 per share to cover tax withholding obligations.
The footnote clarifies that no shares were issued or sold on the open market; the shares were retained by the company to satisfy taxes. After this withholding transaction, Taylor directly owns 4,945 shares of Sanara MedTech common stock.